Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joint Stock Company PharmaceutfiledCriticalJoint Stock Company Pharmaceut
Priority to UA2001020981ApriorityCriticalpatent/UA40451C2/en
Publication of UA40451ApublicationCriticalpatent/UA40451A/en
Publication of UA40451C2publicationCriticalpatent/UA40451C2/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
The method for manufacture of the encapsulated dosage form consists in mixing sodium diclofenac with the liquid paraffin and lactose. The mixture is moistened with 40% solution of Oidragit RL in ethanol. The wet granulate is dried and calibrated. The pellets are covered with the film coating based on Oidragit RL. The pellets are powdered with calcium stearate. The coating is accompanied with the continuous drying in air flow. 10% solution of Oidragit RL in ethanol is used for coating. The final content of sodium diclofenac is 0.075 g per one capsule of 0.25 g.
UA2001020981A2001-02-132001-02-13Method for manufacture of encapsulated dosage form
UA40451C2
(en)
New inhalation preparation having a liquid concentration of 0.28 to 0.38 g / ml containing terbutaline sulphate, method of preparation and use of the preparation